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Abstract
Uncomplicated infections of the urinary tract, caused by uropathogenic Escherichia coli, are among the most common
diseases requiring medical intervention. A preventive vaccine to reduce the morbidity and fiscal burden these infections
have upon the healthcare system would be beneficial. Here, we describe the results of a large-scale selection process that
incorporates bioinformatic, genomic, transcriptomic, and proteomic screens to identify six vaccine candidates from the 5379
predicted proteins encoded by uropathogenic E. coli strain CFT073. The vaccine candidates, ChuA, Hma, Iha, IreA, IroN, and
IutA, all belong to a functional class of molecules that is involved in iron acquisition, a process critical for pathogenesis in all
microbes. Intranasal immunization of CBA/J mice with these outer membrane iron receptors elicited a systemic and mucosal
immune response that included the production of antigen-specific IgM, IgG, and IgA antibodies. The cellular response to
vaccination was characterized by the induction and secretion of IFN-c and IL-17. Of the six potential vaccine candidates,
IreA, Hma, and IutA provided significant protection from experimental infection. In immunized animals, class-switching from
IgM to IgG and production of antigen-specific IgA in the urine represent immunological correlates of protection from E. coli
bladder colonization. These findings are an important first step toward the development of a subunit vaccine to prevent
urinary tract infections and demonstrate how targeting an entire class of molecules that are collectively required for
pathogenesis may represent a fundamental strategy to combat infections.
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Introduction
The urinary tract is among the most common sites of bacterial
infection. Over half (53%) of all women and 14% of men
experience at least one urinary tract infection (UTI) in their
lifetime [1,2], leading to an average of 6.8 million physician office
visits, 1.3 million emergency room visits, and 245,000 hospital-
izations per year, with an annual cost of over $2.4 billion in the
United States alone [3]. Escherichia coli is the infectious agent in
more than 80% of uncomplicated UTIs, which occur in patients
with an anatomically normal urinary tract devoid of structural
abnormalities or inflammatory lesions [4].
In addition to symptoms of acute cystitis and pyelonephritis
caused by UTI, a number of more serious conditions are often
associated with these infections. Upper UTIs in young children
can cause permanent kidney damage. An estimated 57% of
children with acute pyelonephritis develop renal scarring [5].
UTIs are classically treated with trimethoprim/sulfamethoxazole
or ciprofloxacin to eradicate the infecting strain. However, there is
documentation of increasing resistance to these antibiotics [6].
Furthermore, following successful primary treatment, recurrent
infections frequently occur, with an estimated 27% of women
experiencing a recurrence within six months of the original
infection and 2.7% experiencing a third infection during this time
[7]. The reservoir for reinfection remains unclear, with same-
strain episodes making up between 25–100% of recurrent UTI
cases [reviewed in [8]]. Consequently, these complications pose a
significant challenge to UTI treatment and suggest that a vaccine
to prevent UTI would alleviate this major source of morbidity and
economic burden.
Indeed, a number of groups have sought to stimulate protective
immunity against UPEC. Early studies utilized various capsular
and LPS core antigens and heat-killed bacteria to elicit protective
immune responses [9,10]. Recently, whole cell or cell extract
preparations have been shown to provide modest short-term
protection in some individuals [11,12]. Because of their abun-
dance on the cell surface and demonstrated role in UPEC
pathogenesis [13], fimbriae have been attractive targets for defined
protein subunit vaccines. For example, immunization with the
type 1 fimbrial adhesin, FimH, conjugated to its periplasmic
chaperone, FimC, reduced murine bladder colonization by 99.9%,
as well as provided protection in a primate model [14,15].
Additionally, subunit vaccines based on several other surface-
exposed molecules such as P fimbriae (PapDG complex), alpha
hemolysin, Dr fimbriae, the salmochelin receptor IroN, and a
conjugation of capsule polysaccharide K13 with diphtheria toxoid
have been shown to induce at least some immune response in
immunized animals [16–20]. However, although much research
has focused on the development of a vaccine against UPEC, none
are available in the United States.
Large-scale reverse vaccinology approaches offer an alternative
to traditional vaccine design. Pioneered by successful work using
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matic methods to identify novel vaccine targets [21]. Recently
applied to extraintestinal pathogenic E. coli (ExPEC), a pathotype
to which UPEC belongs, a subtractive hybridization study
identified surface-exposed antigens specific to ExPEC and found
that several of these proteins protected immunized mice from
lethal sepsis [22]. Due to the limited success of previous UTI
vaccine design strategies, we hypothesized that a functional
vaccinology approach would identify vaccine targets of UPEC in
an unbiased manner that could elicit protective immunity.
Here we describe the use of previously established genomics and
proteomics data to identify six pathogen-associated outer mem-
brane iron receptors (ChuA, Hma, Iha, IreA, IroN and IutA) as
putative vaccine targets of UPEC. Each of these 71–84 kDa
proteins is predicted to form a transmembrane beta-barrel in the
outer membrane, with a series of loops extending extracellularly
[23]. Facilitating import of specific iron sources, these receptors
mediate uptake of siderophores, secreted bacterial iron-chelating
molecules, or host heme-derived iron. Because iron acquisition is
necessary for bacterial pathogenesis and it is well known that the
urinary tract is an iron-limited environment, iron acquisition via
these receptors is crucial for UPEC infection [24]. Consequently,
deletion of the siderophore receptor IreA, heme receptors ChuA
or Hma, enterobactin receptor Iha, salmochelin receptor IroN, or
aerobactin receptor IutA all decrease the fitness of UPEC in the
murine urinary tract [24–28].
In this study, we demonstrate that an unbiased, rational
vaccinology approach consistently identified a class of molecules
involved in iron acquisition as vaccine candidates and that
intranasal immunization with these UPEC outer membrane iron
receptors provides protection from UTI. Additionally, we show
that antigen-specific antibody and cytokine responses are gener-
ated in response to vaccination with iron receptor proteins, of
which, the former correlated with protection. Therefore, we
propose that this class of molecules is promising as protective
vaccine targets against UPEC and, because of their conserved
function of iron acquisition for pathogenesis, could potentially be




To identify bacterial proteins that could be used as vaccine
targets against UPEC infection, we utilized a functional vaccinol-
ogy approach, combining both genomics and proteomics tech-
niques. To begin, criteria defining UPEC vaccine targets were
established and data from our previously-described studies
assembled to identify proteins meeting these requirements. Of
the 5379 predicted proteins in E. coli pyelonephritis strain
CFT073, only six proteins (Table 1) met all five of our established
criteria: high in vivo expression, induction during growth in human
urine, surface exposure, antigenicity, and pathogen-specificity.
Transcriptomic and proteomic data were evaluated to identify
candidates meeting the expression and antigenicity criteria. Data
from an in vivo transcriptome study indicated that genes encoding
iron acquisition system components were among those most highly
upregulated in CFT073 isolated from the urine of experimentally
infected CBA/J mice [29]. When all genes were ranked in order of
expression level in vivo, these iron acquisition genes, specifically
outer membrane iron receptors, were among the top 18% most
highly expressed in the murine urinary tract (Table 1). Similarly,
when outer membrane proteins (OMPs), which are partially
surface-exposed, were isolated from CFT073 cultured in human
urine ex vivo and compared with OMPs isolated from bacteria
cultured in Luria broth, these iron receptors were the most highly
Author Summary
Because urinary tract infections (UTIs) are a significant
healthcare burden, it would be beneficial to develop a
vaccine to prevent uncomplicated UTI caused by Esche-
richia coli. Using a large-scale screening process we
uniformly identified proteins involved in iron uptake as
potential vaccine candidates against E. coli. Iron acquisition
is a critical function required by bacteria in order to cause
infections. In uropathogenic Escherichia coli, this function
is mediated by a repertoire of systems that scavenge iron
from the host during infection. We found that vaccination
with certain iron receptors from these systems is sufficient
to elicit protective immunity from experimental urinary
tract infection. Induction of an antibody response played a
key role in protection from infection because antibody
class-switching and the production of antibodies in urine
correlated with reduced numbers of bacteria in the
bladder. By targeting an entire class of molecules involved
in iron acquisition instead of a single protein, it was
possible to successfully identify components of a protec-
tive UTI vaccine. This strategy could be a useful approach
in the development of vaccines to prevent infections
caused by other pathogenic bacteria.
Table 1. Candidate antigens and selection criteria.
Gene Locus tag Fold change in vivo
a in vivo percentile
b Fold change in human urine
c Antigenic
d % UPEC (n=55)
e % fecal (n=30)
e
chuA c4308 7.06 95.0 27.8 + 87 30
hma c2482 6.56 94.5 14.8 + 69 17
iha c3610 18.9 89.1 5.87 + 45 37
ireA c5174 23.3 95.2 7.81 + 20 17
iroN c1250 22.7 82.7 7.63 + 71 33
iutA c3623 5.57 97.0 49.2 + 65 17
aTranscript fold change in the urine of experimentally infected mice as compared to growth in LB [29].
bOf 5379 genes ranked in order of in vivo transcript microarray signal intensity [29].
cProtein fold change following growth in pooled filter-sterilized human urine as compared to growth in LB [30].
dReacts with sera from mice chronically infected with E. coli CFT073 [31].
ePrevalence of indicated gene in UPEC and fecal isolates [31].
doi:10.1371/journal.ppat.1000586.t001
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Table 1 comprised six of the top seven human urine-induced
OMPs. In addition to bacteria isolated from urine, our and other
groups have observed expression of these outer membrane iron
receptors by bladder cell-associated UPEC, both in vitro [31] and in
vivo [32]. Finally, an immunoproteomics study identified these iron
receptors as antigenic; that is, they reacted with antisera from mice
chronically infected with UPEC strain CFT073, indicating that
these proteins elicited a humoral response during experimental
UTI [31].
As UPEC strains represent a subset of strains that are genetically
distinct from commensal E. coli, a vaccine directed against UPEC
should specifically target pathogenic strains. Toward this end, a
comparative genomics hybridization study identified 131 genes
that were present in all UPEC strains analyzed (n=10), but none
of the fecal-commensal E. coli isolates tested (n=4) [33]. Among
these UPEC-specific genes were two encoding outer membrane
heme receptors, chuA and hma. Furthermore, dot blot analysis of a
collection of UPEC and fecal-commensal E. coli isolates identified
several of these iron OMP genes (chuA, hma, iroN, and iutA)a s
present more frequently among pathogens than non-pathogens
[31]. Even genes that were not statistically more frequent among
uropathogens (iha and ireA) were nonetheless present at relatively
low frequencies in commensals.
Of the 5379 predicted proteins in UPEC strain CFT073, six
candidate antigens, all outer membrane iron receptors, emerged
from our series of genomics and proteomics studies as uniformly
highly ranked potential vaccine targets (Table 1). This screening
process strongly suggested that broadly targeting an entire class of
molecules involved in iron acquisition could be an effective
strategy to develop a protective UTI vaccine.
Vaccination confers protection against experimental UTI
The six iron receptor vaccine candidates, ChuA, Hma, IutA,
IreA, Iha, and IroN were expressed and purified as affinity-tagged
recombinant proteins. Consistent with the predicted structure of
these antigens, the CD spectrum of refolded purified Hma
displayed a trough at 218 nm, which is characteristic of a b-
sheet-rich conformation (Fig. S1). The six purified protein antigens
were each biochemically cross-linked to the adjuvant cholera toxin
(CT) at a ratio of 10:1 (antigen:CT) and groups of mice (n=15–20)
were intranasally inoculated with either an antigen-CT complex or
CT alone. Following primary immunization (day 0) and booster
doses (days 7 and 14), the animals were transurethrally challenged
with UPEC strain CFT073 and protection was assessed at 48 h
post infection (hpi) by determining CFUs in the urine, bladder,
and kidneys.
Of the six candidates, three conferred protection against
experimental challenge with UPEC. The heme receptor, Hma,
protected mice against colonization of the kidney. Hma-vaccinat-
ed mice demonstrated nearly a 3-log reduction in median CFU/g
in the kidney (P=0.008) and 13/20 mice had undetectable levels
of bacteria (,100 CFU/g) in the kidneys (Fig. 1B). The putative
siderophore receptor IreA showed significant protection and
demonstrated a 3-log reduction in median CFU/g in the bladder
(P=0.035) (Fig. 1D). For IreA, 9/15 vaccinated mice had
undetectable levels of bacteria in the bladder. The siderophore
receptor for aerobactin, IutA, conferred significant protection
against UPEC challenge in both the bladder and kidneys. Mice
vaccinated with IutA displayed one-log CFU/g reduction in both
the bladder (P=0.009) and kidneys (P=0.007) (Fig. 1E). This
showed that mucosal immunization in the nares generates a
protective effect at distal sites, the bladder and kidneys. Not all
antigens selected as candidates provided protection against
experimental UTI. Both ChuA and Iha recombinant proteins
when cross-linked to cholera toxin failed to elicit significant
protection against challenge with UPEC strain CFT073 (Fig. 1A
and C). All of the native protein vaccines were well tolerated in
immunized mice and no animals died following vaccination, with
the exception of ChuA, which was lethal in 11/30 mice (surviving
mice were not protected).
Since a significant reduction in post-challenge CFU was
observed for Hma and IreA vaccinated mice, these antigens were
tested to determine if similar levels of protection could be
generated following heterologous challenge with another UPEC
isolate. Groups of 20 mice were immunized as described with
either Hma, IreA, or CT alone and CFU were determined at 48
hpi following challenge with UPEC strain 536. In these
experiments, Hma vaccinated mice were significantly protected
from heterologous challenge and displayed .10-fold reduction in
median CFU/g in the bladder (P=0.0287) (Fig. 2). Vaccination
with IreA significantly protected mice from infection with UPEC
strain 536 and these mice demonstrated a log-fold decrease in
median CFU/g in the kidneys (P=0.0379) (Fig. 2).
Peptides (30 aa) corresponding to single predicted extracellular
loops in both the salmochelin siderophore receptor IroN (aa 491–
520) and aerobactin receptor IutA (aa 467–498) were also assessed
to determine their use as potential immunogens. Extracellular
loops were selected based on their predicted topology to direct an
antibody response against surface exposed residues. These
peptides also represent highly conserved loops within the
salmochelin and aerobactin receptors; the IroN peptide has
.90% identity to 37 siderophore receptor sequences including
urinary tract isolates 536, UTI89, and 83972. The IutA peptide
has .76% identity (23/30 aa) among 15 aerobactin receptor
sequences present in various pathogenic E. coli, including
uropathogenic and extraintestinal isolates UMN026 [34], IAI39,
and S88 [35]. Groups of mice (n=15) were inoculated as
previously described with either peptide mixed with CT or CT
alone and protection was assessed at 48 hpi following infection
with UPEC strain CFT073. These peptides failed to elicit
significant protection in the urine, bladder, or kidneys of mice,
however, there was nearly a 2-log reduction in CFU/g in the
kidneys for both IroN (P=0.053) and IutA (P=0.078) peptides,
demonstrating a strong trend towards protection (Fig. 1F). These
results imply that peptides may be suitable for development of a
UTI vaccine but may be more efficacious if cross-linked or fused to
a carrier molecule. Together, these findings show that targeting an
entire functional class of molecules involved in iron acquisition is
an effective strategy to identify protective vaccine candidates that
significantly reduce bacterial colonization during ascending UTI
following experimental challenge with UPEC.
Antigen-specific splenocytes from vaccinated mice
secrete IFN-c and IL-17
Proinflammatory cytokines are crucial for orchestrating protec-
tive immune responses against pathogens. Secretion of two major
proinflammatory cytokine mediators, IFN-c and IL-17A (IL-17),
were measured from the splenocytes of mice immunized with
adjuvant alone (CT), IreA (a protective antigen), or Iha (a non-
protective antigen) following vaccination. Cells were analyzed both
pre- and post-challenge to gauge the immune response to antigenic
stimulation in vivo. Splenocytes were cultured in vitro in the
presence of 1 mg/ml of the corresponding purified antigen used for
immunization. Cytokines were measured in the supernatant by
ELISA after 48 h incubation. Splenocytes from Iha-vaccinated
and IreA-vaccinated mice collected both before (2) and after (+)
challenge demonstrated significant antigen-specific secretion of
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PLoS Pathogens | www.plospathogens.org 3 September 2009 | Volume 5 | Issue 9 | e1000586Figure 1. Immunization with outer membrane iron receptor antigens protects against urinary tract colonization by E. coli CFT073.
CBA/J mice were intranasally vaccinated as described with a primary dose of 100 mg purified protein crosslinked to 10 mg CT (A–E) or 100 mg peptide
mixed with 10 mg CT (F), followed by 2 boosts of 25 mg antigen crosslinked to 2.5 mg CT or mixed with CT for peptides. One week following the final
boost, animals were transurethrally challenged with 1610
8 CFU of E. coli CFT073 and colonization was measured 48 hpi. Symbols represent CFU/g
tissue or /ml urine of individual mice and bars indicate median values. Clear bars, mock vaccinated with CT alone; gray bars, vaccinated with purified
(A) ChuA, (B) Hma, (C) Iha, (D) IreA, or (E) IutA, or (F) peptides IroN (light gray bars) or IutA (dark gray bars). Dashed line shows the limit of detection for
this assay, 100 CFU/g. Significance was determined using a one-tailed Mann-Whitney test.
doi:10.1371/journal.ppat.1000586.g001
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from CT control mice (P,0.05) (Fig. 3A and B). Unstimulated
splenocytes from any group of mice lacked detectable levels of
IFN-c or IL-17 (data not shown). Interestingly, splenocytes derived
from Iha- and IreA-vaccinated mice post-challenge secreted less
pro-inflammatory cytokines than pre-challenge cells (P,0.003)
(Fig. 3A and B). Both IFN-c and IL-17 secreting splenocytes were
significantly decreased post-challenge (P,0.003) in IreA-vaccinat-
ed mice (Fig 3B), whereas only IL-17 secreted splenocytes were
significantly decreased (P=0.0007) in mice vaccinated with Iha
(Fig. 3A). Overall, these results indicated that vaccinated mice
generate antigen-specific cells that are capable of secreting IFN-c
and IL-17, two important pro-inflammatory cytokine mediators, in
response to in vitro restimulation. No significant correlation was
found between cytokine production and reduction in CFU post-
challenge. However, the decrease in both IFN-c and IL-17
secretion from vaccinated mice post-challenge as compared to pre-
challenge was only observed following immunization with antigens
that protected mice from infection (Fig. 3B) and was not seen
following immunization with non-protective antigens (Fig. 3A).
Vaccinated mice secrete antigen-specific IgA in urine
To evaluate the humoral immune response at the primary site
of infection, the bladder mucosa, levels of antigen-specific IgA in
urine were measured by ELISA. To account for variability in the
amount and concentration of urine from each mouse, collections
were pooled for use in an indirect ELISA to measure antigen-
specific IgA. Urine from IreA- (Fig. 4A) and IutA-vaccinated
(Fig. 4B) cohorts, which had significantly decreased bladder
colonization upon challenge, had the highest fold increases in IgA
(34-fold and 6.2-fold, respectively) post-vaccination. Antigens that
did not generate significant decreases in colonization in the
bladders of vaccinated mice had more modest fold-increases in
urine IgA post-vaccination (2.2-fold for Hma, 2.0-fold for ChuA,
and 1.7-fold for Iha) (Fig. 4C–E). Correspondingly, peptide
antigens representing extracellular loops of IroN and IutA did
not significantly protect from infection in the bladder, and IgA was
at background levels in the urine of these animals (Fig. 4F). These
findings demonstrate that vaccination with antigens, IreA and
IutA, which provide significant protection in the bladder from
experimental challenge with UPEC, generate significant induction
of antigen-specific IgA secretion that is detectable in urine of
immunized animals.
Vaccinated mice produce antigen-specific serum
antibodies
To evaluate the systemic humoral immune response to our
vaccine candidates, the levels of serum antigen-specific antibodies
generated by vaccinated mice were compared to those of CT
control mice. Serum was collected by infraorbital ocular bleed
before vaccination and after vaccination prior to transurethral
challenge with UPEC strain CFT073. For each protein and loop
peptide antigen tested, there was a significant increase of antigen-
specific IgG in post-vaccination serum compared to the corre-
sponding pre-immune serum (P=0.0002) (Fig. 5A–F). In most
cases, there was no difference in IgG levels between the pre- and
post-vaccinated sera from CT control mice. Additionally, all post-
vaccination sera had significantly higher levels of IgM than pre-
vaccination sera (P,0.05) (Fig. 5A–F). Although both IgG1 and
IgG2a increased from pre- to post-vaccination, there was no skew
toward production of IgG1 or IgG2a in any group (data not shown).
This phenomenon is not unusual for protein antigens, as they can
stimulate production of both Th1 and Th2 cells by virtue of their
broad MHC class II peptide repertoire [36]. None of the samples
tested showed appreciable increases in serum IgA (data not shown).
These findings show that vaccinated mice generate target-specific
antibodies, both innate IgM and class-switched IgG in response to
intranasal immunization with iron-receptor antigens.
Figure 2. Immunization with Hma and IreA reduces colonization by E. coli 536. CBA/J mice were intranasally vaccinated as described with a
primary dose of 100 mg purified protein crosslinked to 10 mg CT (open circles) or CT alone (closed circles), followed by 2 boosts of 25 mg antigen
crosslinked to 2.5 mg CT or CT alone. One week following the final boost, animals were transurethrally challenged with 1610
8 CFU of E. coli 536 and
colonization was measured 48 hpi. Symbols represent CFU/g tissue or /ml urine of individual mice and bars indicate median values. Clear bars, mock
vaccinated with CT alone; gray bars, vaccinated with purified Hma or IreA. Significance was determined using a one-tailed Mann-Whitney test.
doi:10.1371/journal.ppat.1000586.g002
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with protection
IgG and IgM are often monitored to determine the level of class
switching undergone by B cells. In our studies, all vaccinated
animals demonstrated significant increases in both serum IgG and
IgM from pre- to post-vaccination. However, Hma-, IreA-, and
IutA-vaccinated (protected) animals displayed more dramatic IgG
increases than IgM when compared to ChuA-, Iha-, and peptide
loop antigen-vaccinated (unprotected) animals (compare Fig. 5B, D,
and E to Fig. 5A, C, and F). This finding suggested that these
animals have been sufficiently stimulated to class switch to more
effective antibody isotypes. To more quantitatively assess this trend
and the relationship of serum IgG and IgM to protection from UTI,
wefirstcalculatedaClassSwitchIndexusingthedata from allofthe
immunizedmice (n=203).TheClass SwitchIndexistheratioofthe
median change in sera IgG to the median change in sera IgM for
each group of vaccinated mice. To account for an increase in non-
specific antibodies, the median changes in sera IgG and IgM of CT-
treated mouse cohorts were subtracted from the corresponding
antigen-vaccinated group values. The class switch indices were then
plotted against the normalized post-challenge median bladder
CFU/g to determine if any relationship existed between antibody
class-switching and protection from cystitis. Because infectivity can
vary between experiments, the median CFU/g from each antigen-
vaccinated group was divided by the median CFU/g of the CT
control group for normalization. Finally, both the Class Switch
Index and normalized median CFU/g values were log10 trans-
formedfor comparison ona linearscale. This analysis demonstrated
that there was a significant correlation between the Class Switch
Index and the CFU/g in the bladder (P=0.0014) (Fig. 6A),
suggesting that a decrease in bladder colonization may be attributed
to the relative amount of antibody class-switching from IgM to IgG
in mice vaccinated with protective antigens. No significant
correlation was found between antibody class-switching from IgM
to IgG and CFU/g in the kidneys. However, as predicted, there is
alsoa strong correlation between the amount of antigen-specificIgA
in urine and protection from UPEC infection in the bladder
(Fig. 6B); specifically, increases in urine IgA corresponded to
decreases in bladder CFU (P=0.0165). These findings show that
antibody class-switching and urinary IgA are each an immunolog-
ical correlate of protection against UTI caused by E. coli.
Discussion
UTIs caused by UPEC represent a significant healthcare burden
that could be alleviated by the development of a vaccine that would
provide protection from these infections. Toward this aim, we
described the use of a multi-pronged, functional vaccinology
approach that uniformly singled out one class of molecules, those
involved in iron acquisition, as potential targets. The screening
process selected six vaccine candidates from the 5379 predicted
proteins encoded within the E. coli CFT073 genome. The six
vaccine candidates meet all of the following criteria: predicted to be
surface-exposed, present in the bacterial outer membrane [30,31],
conserved among UPEC strains [31,33], transcriptionally upregu-
lated in vivo [29], induced during culture in human urine [30], and
antigenic [31]. These vaccine targets, ChuA, Hma, Iha, IreA, IroN,
and IutA, are all outer membrane b-barrel proteins that function as
receptors for iron-containing compounds. Of these, we found that
intranasal immunization with Hma, IreA, or IutA generates an
antigen-specific humoral response, antigen-specific production of
IL-17 and IFN-c, and provides significant protection against
experimental infection with UPEC.
Site-specific protection was observed for the antigens that
provided the greatest reduction in bacterial counts, Hma and IreA.
Mice immunized with the IreA vaccine were significantly
protected from CFT073 colonization only in the bladder, with
.2-log reduction in the median CFU/g and 60% of mice having
undetectable levels of bacteria within that organ. The dramatic
reduction in the level of bacterial colonization within the bladder
may have resulted in reduced numbers of bacteria ascending to the
kidneys that could account for the modest reduction in bacteria
Figure 3. Antigen-specific splenocytes from vaccinated mice
secrete IFN-c and IL-17. Splenocytes harvested from (A) Iha-
vaccinated or (B) IreA-vaccinated without challenge (2) or two days
after transurethral challenge with E. coli CFT073 (+) were stimulated
with the corresponding antigen in vitro. Cytokines were measured in
culture supernatants by ELISA. Open circles represent CT control-
treated mice and closed circles represent iron receptor antigen-
vaccinated mice. Each circle represents an individual animal and bars
represent the median. Significance was determined using a two-tailed
Mann-Whitney test.
doi:10.1371/journal.ppat.1000586.g003
Development of a UTI Vaccine
PLoS Pathogens | www.plospathogens.org 6 September 2009 | Volume 5 | Issue 9 | e1000586seen in the kidneys in the IreA-vaccinated mice following
challenge with either UPEC strain CFT073 or 536.
In contrast to the bladder protection seen with IreA, Hma
significantly reduced the number of bacteria colonizing the kidneys
and, in over half of the animals, prevented kidney colonization
completely. Despite the significant protection in the kidney,
immunization with the Hma vaccine did not reduce the level of
bacteria able to colonize the bladder. The kidney-specific protection
of the Hma vaccine may reflect the biological function of Hma for
UPEC during colonization of the urinary tract, UPEC that are
unable to produce Hma have reduced fitness only within the kidney
during experimental UTI [28]. The site-specificity for the Hma
vaccines suggests that the immune response may perturb the normal
function of this outer membrane heme receptor, perhaps by antibody
interference with ligand-binding domains or selective immune
targeting of bacteria that exhibit tissue-specific expression of Hma.
Induction of the cytokines IL-17 and IFN-c suggests that the
cellular response may be important for the generation of a
protective immune response. To assess cellular responses to
immunization, we analyzed antigen-specific production of two
cytokines known to be critical for mediating anti-bacterial activities
within the host, IFN-c and IL-17, from splenocytes post-
immunization both before and after challenge. Production of
IFN- c has been previously shown to be important for the control
of infection within the urinary tract [37] and IL-17 has been
shown to promote the recruitment of neutrophils in response to
bacterial infection [38]. IL-17 has been recently appreciated as an
important mediator to control infection by Salmonella, Listeria,
pathogenic Mycobacterium, E. coli, and Klebsiella [39–43]. Both IFN-
c and IL-17 were produced in response to immunization with IreA
and Iha. Splenocytes obtained from vaccinated mice post-
challenge showed a reduction in antigen-specific cytokine secretion
of IFN- c and IL-17, suggesting that antigen-specific lymphocytes
may be homing from the spleen to the site of infection. Further,
the post-challenge reduction in both antigen-specific cytokines
tested was only significant for the IreA vaccine, which generates a
protective response in the bladder.
Mucosal immunization is considered the most effective means to
develop a UTI vaccine and we have shown previously that
intranasal immunization with MR/P fimbria is effective in
protecting mice against UTI caused by Proteus mirabilis, an agent
of complicated UTI [44]. Because local immunization of the
urethra is not practical, the migration of immune cells between
mucosal sites can be exploited during intranasal inoculation with
antigen [45]. We reasoned that intranasal immunization would
generate a distant mucosal response in the genitourinary tract
against UPEC in vaccinated animals. Consistent with this, we
observed that the two vaccines, IreA and IutA, which conferred
significant protection in the bladder, had the greatest antigen-
specific production of secretory IgA detectable in their urine. For
the IreA vaccine, the increase in IgA in urine provides evidence
that may account for the bladder-specific protection seen in mice
immunized with this vaccine. Conversely, antigens that did not
induce protective immunity within the bladder did not generate a
similar increase in the level of IgA. Based upon these findings,
relative levels of IgA in the urine significantly correlated with
protection in the bladder. That is, when examining all of the
vaccine candidates and bacterial counts within the bladder, there
is a direct relationship between a reduction in CFU in the bladder
and increased IgA in the urine. This immunological correlate
suggests that a mucosal response and vaccine that generates IgA is
sufficient to provide protection from UPEC colonization in the
Figure 4. Mice produce antigen-specific urinary IgA in response to intranasal immunization. Urine from (A) IreA-vaccinated, (B) IutA-
vaccinated, (C) Hma-vaccinated, (D) Iha-vaccinated, (E) ChuA-vaccinated, (F) peptide-vaccinated, and corresponding CT control mice was collected
prior to vaccination (pre) and after vaccination but before transurethral challenge with UPEC strain CFT073 (post). Pooled samples were plated in
appropriately coated ELISA plates and probed for antigen-specific IgA. Open bars represent CT control mice and shaded bars represent values from
vaccinated mice. Absorbance reflects relative quantity of IgA. Error bars indicate the mean+/2SEM of two experiments.
doi:10.1371/journal.ppat.1000586.g004
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PLoS Pathogens | www.plospathogens.org 7 September 2009 | Volume 5 | Issue 9 | e1000586Figure 5. Antigen-specific serum IgM and IgG is produced in vaccinated mice. Serum from (A) ChuA-vaccinated, (B) Hma-vaccinated,
(C) Iha-vaccinated, (D) IreA-vaccinated, (E) IutA-vaccinated, (F) IroN and IutA extracellular loop peptide antigens and corresponding CT control-treated
mice was collected prior to vaccination (pre) and after vaccination before transurethral challenge with UPEC strain CFT073 (post). Samples were
plated in duplicate in appropriately coated ELISA plates and probed for relative IgG and IgM. Open circles represent CT control mice and closed
circles represent vaccinated mice. Each circle represents an individual animal and bars represent the median. Significance was determined using a
two-tailed Mann-Whitney test.
doi:10.1371/journal.ppat.1000586.g005
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shown that antibodies specific for the infecting E. coli strains leads
to resolution of cystitis and that oral immunization with outer
membrane proteins generates an antigen-specific IgA mucosal
response against UPEC [46,47].
The finding that IgA in the urine is produced in response to
intranasal immunization indirectly shows that class-switching of
antibody isotypes is occurring in vaccinated animals. Analysis of
serum antibodies from immunized mice shows that antigen-
specific IgM is produced in response to all the vaccine candidates
tested. Further, antigen-specific IgG is markedly increased in
response to each vaccine when compared to pre-immune sera. For
the Hma and IutA vaccines, which provided significant protection
in the kidney, it is possible that circulating IgG or antigen-specific
plasma cells contribute to the observed reduction of bacterial
colonization. Interestingly, the vaccines that significantly protected
mice against UPEC infection, Hma, IreA, and IutA, displayed a
dramatic increase in antigen-specific IgG relative to IgM. This
suggests that class-switching of antibody isotypes is indicative of a
protective immune response. To assess this effect, we defined a
Class Switch Index by comparing the ratio derived from the
median changes in antigen-specific IgG to that of IgM, normalized
to CT and plotted those values against the CT-normalized log-
ratio of CFU/g in the bladder post-challenge. By plotting
normalized CFU/g values against the Class Switch Index, we
found a significant correlation between class-switching antibody
isotypes and protection from bacterial colonization in the bladder.
There has been limited success to develop an efficacious UTI
vaccine that would provide protection from infection by UPEC.
Immunization with Solco-Urovac, a vaccine formulation that is
comprised of inactivated uropathogenic bacteria, generates
urinary IgA [48] and vaginal immunization with this vaccine
provides protection that lasts 8–12 weeks in humans [11]. If
administered more frequently, vaccination with Solco-Urovac can
increase time to recurrence to six months [49]. This suggests this
vaccine might be useful to prevent recurrent UTIs in susceptible
populations. The major Type 1 fimbrial adhesin of UPEC, FimH,
has also been used as a vaccine candidate and provided protection
in mice [14] and prevented bacteriuria in primates [15]. One of
the vaccine candidates we identified and tested, IroN, has been
used previously to immunize mice, and similar to our results with
IroN, was shown to generate antigen-specific IgG but not IgA
[17]. In contrast to our findings, this group found that IroN
protected mice against renal infection. This difference could be
accounted for by the fact that we used an IroN extracellular loop-
derived peptide mixed with CT and the previous study used
denatured protein without adjuvant [17]. More recently, it has
been shown that intranasal immunization with formalin-killed
UPEC lacking capsular polysaccharides and O antigen generates a
specific humoral response in mice; however, the protective efficacy
of this vaccine is not known [50]. Lastly, using a lethal challenge
model of extraintestinal pathogenic E. coli infection, it was found
that vaccination with IroN, but not ChuA, increased survival in
immunized mice [22].
Despite these advances, a UTI vaccine that confers long-term
protection against uncomplicated UTIs is currently lacking. The
rational large-scale screening process we described identified six
surface-exposed outer membrane receptors for iron compounds.
These represent vaccine candidates because they are conserved
among uropathogenic strains and largely absent from commensal
bacteria, induced during growth in human urine and during
experimental UTI, and are antigenic. Iron acquisition is well
known to be a common trait necessary for bacterial pathogenesis
and by targeting receptors involved in this process it may be
possible to disrupt this critical function in addition to pathogen
neutralization and opsonization. Intranasal inoculation with three
of six vaccine candidates (IreA, Hma, IutA) provided protection
from challenge with uropathogenic E. coli and this study provides
the basis for the development of a subunit vaccine that would
incorporate these protective antigens to provide broader efficacy
within the urinary tract and across uropathogenic isolates.
Figure 6. Isotype class-switching and urinary IgA correlates with
vaccine-mediated protection from infection. (A) The Class Switch
Index was calculated by dividing the changein serum IgGabsorbance for
the entire group of vaccinated mice (accounting for non-specific
increases by subtracting the corresponding median change in IgG
absorbance for the CT-vaccinated mouse cohort) by the same
computation preformed with group median IgM absorbance values
[(DIgGVAC2DIgGCT)/(DIgMVAC2DIgMCT)]. The Class Switch Index was
then plotted against thenormalized bladder CFU(groupmedianCFUVAC/
group median CFUCT) for each vaccination experiment. Thus, each
individual point reflects the collective data from an experiment involving
10 vaccinated and 10 CT mice (n=203). Lower normalized CFU values
indicate enhanced bacterial clearance after challenge, where higher class
switch indices represent superior B cell activation by comparing the
increase in IgG compared to the increase in IgM. (B) Normalized bladder
CFU values from each vaccination experiment are plotted against the
median change in absorbance of antigen-specfic IgA detected in the
urine (DIgAVAC). Pearson correlation coefficient (r) and P values are
shown.
doi:10.1371/journal.ppat.1000586.g006
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proteins that are involved in a singular function necessary for
pathogenesis rather than a single protein may be fundamental
strategy that could be generally adopted during the development
of vaccines against pathogens.
Materials and Methods
Bacterial strains and culture conditions
E. coli strain CFT073 was isolated from the blood and urine of a
patient with acute pyelonephritis [51]. E. coli strain 536 was isolated
from a patient with acute pyelonephritis [52]. Unless otherwise
noted, bacteria were cultured in Luria broth (LB) containing
appropriate antibiotics (100 mg/ml ampicillin, 25 mg/ml kanamy-
cin, and/or 20 mg/ml chloramphenicol) at 37uC with aeration.
Murine model of ascending UTI
Female CBA/J mice were transurethrally inoculated as
previously described [53]. Prior to inoculation, overnight E. coli
CFT073 cultures were harvested by centrifugation (30006g,
30 min 4uC) and resuspended in PBS to an OD600 of 4.0,
equivalent to 4610
9 CFU/ml. Bacterial suspension (50 ml/mouse)
was delivered transurethrally using a sterile 0.28 mm inner
diameter polyethylene catheter connected to an infusion pump
(Harvard Apparatus), with total inoculum of 1610
8 CFU/mouse.
For determination of CFUs, organs were harvested from
euthanized animals at 48 h post-inoculation and homogenized in
PBS with a GLH homogenizer (Omni International). Bacteria in
tissue homogenates were enumerated by plating on Luria-Bertani
agar containing 0.5 g/L NaCl using an Autoplate 4000 spiral
plater (Spiral Biotech). Colonies were enumerated using a QCount
automated plate counter (Spiral Biotech).
Blood was collected as necessary from anesthetized mice by an
infraorbital bleed using 1.1 to 1.2 mm Micro-Hematocrit Capillary
Tubes (Fisher) and serum was separated using Microtainer Serum
Separator Tubes (Becton Dickinson). Six- to eight-week old mice
were used for these studies and animals were #15 weeks old at the
conclusion of all experiments. All procedures were conducted
according to protocols approved by University Committee on the
Care and Use of Animals at the University of Michigan.
Antigen purification
Genes encoding the selected antigens were PCR-amplified from
CFT073 genomic DNA and cloned into either pBAD-myc-HisA
(Invitrogen) or pET30b+ (Novagen). Recombinant protein
expression from pBAD (Hma, IutA, ChuA) was induced in E.
coli TOP10 cultured to OD600=0.8 by addition of L-arabinose to
100 mM for 4 h. Proteins expressed from pET (Iha, IreA) were
over-expressed in E. coli BL21(DE3) pLysS cultured in Terrific
broth (12 g/L tryptone, 24 g/L yeast extract, 2.3 g/L KH2PO4,
12.5 g/L K2HPO4, 4% glycerol) to OD600=1.0 at 37uC and
induced overnight with 1 mM isopropyl b-D-1-thiogalactopyrano-
side (IPTG).
Induced cultures were harvested by centrifugation (8,0006g,
4uC, 10 min), resuspended in 10 mM HEPES, pH 7, and 100 U
Benzonase nuclease (Sigma). Bacteria were lysed by two passages
though a French pressure cell (20,000 psi) and the lysate was
cleared by centrifugation (8,0006g,4 uC, 10 min). Bacterial
membranes were pelleted from the cleared lysate by ultracentri-
fugation (112,0006g,4 uC, 30 min) and the membrane pellet
resuspended in 5 ml 100 mM NaH2PO4, 10 mM Tris-HCl, 8 M
urea, 1% ASB-14, pH 8.0. His6-tagged proteins were purified on
nickel-nitriloacetic acid-agarose columns (Qiagen) under denatur-
ing conditions according to the manufacturer’s instructions (The
QIAexpressionist). Eluted purified proteins were renatured by
dialysis at 4uC into a final solution containing 0.05% Zwittergent
in PBS, pH 7.5 and quantified using the BCA protein assay
(Pierce).
Peptide synthesis
Putative extracellular loops of IroN and IutA were predicted using
the PRED-TMBB program (http://biophysics.biol.uoa.gr/PRED-
TMBB/). 30-mer peptides corresponding loop 6 of IutA and loop 7
of IroN (IroN: YLLYSKGNGCPKDITSGGCYLIGNKDLDPE;
IutA: VDDIDYTQQQKIAAGKAISADAIPGGSVD) were syn-
thesized to $96% purity by Invitrogen.
Vaccination
Purified antigens were chemically cross-linked to cholera toxin
(CT) (Sigma) at a ratio of 10:1 using N-succinimidyl 3-(2-
pyridyldithio) propionate (SPDP) (Pierce) according to the
manufacturer’s recommendations. Peptide antigens were dissolved
in 1 mM EDTA in PBS, mixed with reduced CT, and incubated
at 4uC for 18 h. All immunizations were administered intranasally
in a total volume of 20 ml/animal (10 ml/nare). Animals received a
primary dose on day 0 of 100 mg crosslinked antigen (containing
10 mg CT) or 10 mg CT alone. Two boosts of 25 mg antigen
(crosslinked to 2.5 mg CT) or 2.5 mg CT alone were given on days
7 and 14, and mice were challenged as described above.
Tissue culture
Single-cell suspensions were made from spleens by forcing
organs though 40 mm Cell Strainers (BD Falcon). Red blood cells
were lysed for 2 min using 8.02 mg/ml NH4Cl, 0.84 mg/ml
NaHCO3, 0.37 mg/ml EDTA in distilled water. Final suspensions
were made in RPMI (supplemented with L-Glutamine, Gibco)
with 1% sodium pyruvate, 1% L-glutamine, 1% penicillin/
streptomycin, 1% non-essential amino acids, 10% fetal bovine
serum (FBS), 0.001% 50 mM b-mercaptoethanol. Splenocytes
(1.5610
6 cells/ml) were cultured with either medium alone or with
1 mg/ml purified antigen. After incubation of cells at 37uC, 5%
CO2 for 48 h, supernatants were harvested and stored at 220uC.
ELISA
For indirect serum ELISA, EIA/RIA medium binding 96-well
ELISA plates (Corning) were coated at rt overnight with 5 mg/ml
purified protein (for serum) or 10 mg/ml purified protein (for
urine) diluted in carbonate buffer, pH 9.8. Non-specific binding
sites were blocked with with 10% FBS, 0.04% NaN3 in PBS at
room temp for 1 h. 1:128 dilutions of mouse serum in blocking
buffer or 50 ml of pooled undiluted urine were applied to wells in
two to five replicates. Goat anti-mouse IgA, IgG, and IgM were
obtained conjugated to alkaline phosphatase (Southern Biotech).
Alkaline phosphatase substrate, p-nitrophenyl phosphate (1 mg/
ml) (Sigma), was diluted in carbonate buffer and applied to wells at
rt until color developed. The reaction was stopped with NaOH
and read with a mQuant plate reader (Bio-Tek Instruments, Inc.)
at a wavelength of 405 nm.
For cytokine ELISA, purified IL-17A, IFN-c, and their
corresponding matched antibody pairs were obtained from R&D
Systems and used according to the manufacturer’s recommenda-
tions. For detection, OPD Easy-tablets (2 mg/tablet, Acros
Organics) were diluted and applied until color developed. The
reaction was stopped by addition of 100 ml6NH 2SO4 and read
with a plate reader at a wavelength of 490 nm. Plates were washed
by flooding all wells four times with wash buffer between all
incubations.
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All graphing and statistical analyses were done using GraphPad
Prism 5. Significance was determined using Mann-Whitney tests.
Correlates of protection were determined using the Pearson
correlation coefficient with linear regression to generate a best fit
line. All statistics were conducted using 95% confidence intervals
where applicable.
Supporting Information
Figure S1 Circular dichroism spectrum of purified renatured
Hma. Far UV CD spectral analysis of purified Hma (800 mg/ml)
following buffer exchange and renaturation. Spectrum was
measured from 195 to 250 nm at 25uC using a Jasco Co. (Tokyo,
Japan) J-810 Rev. 1.00 instrument.
Found at: doi:10.1371/journal.ppat.1000586.s001 (0.04 MB PDF)
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